SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets Establishment Inspection Report for Ankleshwar facility

28 May 2026 Evaluate

Lupin has secured the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Ankleshwar facility in Gujarat, India. The EIR has been issued following the closure of a product-specific Pre-Approval Inspection conducted by USFDA from March 2 to March 7, 2026.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2268.10 19.40 (0.86%)
05-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1783.55
Dr. Reddys Lab 1277.80
Cipla 1400.70
Zydus Lifesciences 1088.90
Lupin 2268.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×